DOCSLIB.ORG

Prezentace Aplikace Powerpoint

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Prezentace Aplikace Powerpoint Analgesics - antipyretics = „weak“ analgesics = non-opioid analgesics Most of them also • non-steroidal anti-inflamatory drugs (NSAIDs) •antirheumatics Oldřich Farsa 2011 Metabolism of eicosanoids O O arachidonic O H acid = 2 C O R1 R2 OH R2 O OH CH C O P O + 3 H N CH 2 O 3 CH3 glucocorticoids inhibitors of phspholipase A2 prostaglandins sythesis = COOH = "weak" analgesics + lipoxygenase inhibitors + NSAIDs arachidonic acid cyclooxygenases (COX1 + COX2) lipoxygenase OOH O COOH COOH O PG 5-hydroperoxy-6-trans-8,11,14-cis-eikosatetraenoic acid G2 OOH (5-HPETE) cyklooxygenases tromboxan synthase prostacyklin synthase PG H2 PG I2 = prostacyklin TX A2 endothelium cells LT A4 trombocytes isomerases PG D2 PG E2 LT C4 LT B4 PG F2α all the cells LT D4 LT E4 Effects of prostaglandins ↓ Prostaglandin E, F2α : ache, fewer, inflammation, sekretion of HCl , stomach mucosa capilaries dilatation, contraction of + ↑ uterus, kidneys: excretion of Na and H2O Prostacyclin (prostaglandin I ): vasodilatation, platelets aggregation inhibition 2 Tromboxan: vasokonstriction, platelets aggregation activation Leukotriens: alergic reactions (e.g. asthma bronchiale) Cyklooxygenases (= prostaglandin G/H synthases) COX1 Constitutive: in all the tissues Functions: •protection of stomach mucosa (vasodilatation) •diuresis •platelets aggregation (TXA) COX2 Philipp Needlemann Constitutive: kidneys, brain (co-localized with cyclins D and E) inventor of COX 1 isoenzymes Inducible: macrophages, neutrophfils, fibroblasts, endothelium cells (1989) Functions: •vasodilatation (PG I2) •porod (děložní stahy) childbirth (uterus contractions) •inflammation processes COX3 ?? (= COX1b; brain ?) Classification of COX inhibitors (antipyretics, NSAIDs) Non-selective (COX1 + COX2) •Anilides •Salicylates •Phenamates •Aryl- and heteroaryl alkanoic acids •Aryl- and heteroaryl acetic acids •Aryl- and heteroaryl propionic acids •Oxicames •1,2-Dihydropyrazolidine-3-ones •2,5-Pyrazolidinediones Selective (COX1<COX2): nimesulide Specific (COX2) •Coxibes Anilides HN O HN O HN O OH O acetanilide paracetamol phenacetin (acetaminophen) N-(4-ethoxyphenyl)acetamide N-phenylacetamide 4-(acetylamino)phenol nephrotoxicity 1886: Antifebrin® para-(acetylamino)phenol Dinyl® - analg. p-(acetylamino)phenol mixture with caffeine, Paralen, Panadol…. aminophenazone and barbiturates Paracetamol • inhibits COX only in CNS (COX3 ?) not in periphery ⇒ •effects: analgesic, antipyretic (not antiinflamatory, antirheumatic) Použití ve směsích s(e) Usage in mixtures with HN O •codeine, caffeine ⇒ effect enhancement (Korylan tbl.®, Panadol tbl.®, Efferalgan codein tbl. eff.®) •expectorants (guajfenesin, terpin) •antitussives (dextromethorphan) OH •H1-antihistaminines (pheniramine, chlorphenamine, dimenhydrinate, promethazin, doxylamin) together with α-sympatomimetics (phenylefrine, pseudoephedrine) •spasmolytics (pitophenon) •myorelaxants (chlorzoxan, carisoprodol) •NSAID (acetylsalicylic acid, propyphenazon – Valetol®) Metabolism of paracetamol O O urine 2% urine O S HO O OH O O 42 % 52 % HO O urine conjugation conjugation HO OH N O N O N O CH CH3 3 CH3 paracetamol glucuronide paracetamol sulfate 4 % cytochrome P-450 O R-SH OH R (glutahione, S N-acetylcysteine) R-SH = glutathion ⇒ ⇒ merkapturic acid N O N O CH3 CH3 N-acetyl-p-benzoquinoneimine urine N-(4-oxocyclohexa-2,5-diene-1-ylidene)acetamide NAPQI HEPATOTOXIC Thiols detoxicating N-acetyl-p-benzoquinoneimine γ − Glu-Cys-Gly HS O O O HO N O N H N H H H OH glutathione SH O OH H C N 3 H O N-acetyl-L-cysteine mucolytic ACC®, Mucobene® Synthesis of paracetamol OH OH Sn CH3COOH Morse, Chem. Ber. 11, 232 (1878) HN O NO2 CH3 OH O NO2 2-nitrophenol H3C O OH OH OH OH H3C HNO3 Fe, HCl O HN O NO2 NH2 CH3 phenol 4-nitrophenol 4-aminophenol 4-(acetylamino)phenol Propacetamol – paracetamol prodrug • for intravenous application O Cl + H N O HN O CH3 4-(acetylamino)phenyl-N,N-diethylglycinate hydrochloride 2-[4-(acetylamino)phenoxy]-N,N-diethyl-2-oxoethaneaminium chloride propacetamol hydrochloreid Pro-Dafalgan® (UPSA Laboratoires) O N O H O esterase O H O + N 2 HO HN O HN O CH3 CH 3 Salicylates O HO H3C HO O OH O OH O O hydrolýza H C HO O OH 3 O CH3 oxidace O O HO OH salicin salicylic acid acetylosalicylic acid (2-hydroxymethylphenyl)-β -D-glucopyranoside 2-hydroxybenzoová kys. 2-acetoxybenzoic acid 1827 Leroux: isolation from willow 1838 Piria: the first synthesis since 1878 used as antipyretic 1897 Felix Hoffmann - industrial and antirheumatic synthesis 1899 – Aspirin® (Bayer) Felix Hoffmann Sir John R. Vane Effects of acetylosalicylic acid O OH „Wanted“: •antipyretic O CH3 •analgesic O •anti-inflamatory •antirheumatic •antithrombotic (↓ platelets aggregation) – Anopyrin® „Unwanted“: •ulcerogenic •Rey syndrom in childern after viral infection (hepatopathy, encefalopathy) ⇒ contra-indication in childern •bleeding (e.g. from nose - ↓ platelets aggregation) Intoxication = „salicylism“ – infliction of CNS (psychical malfunctios, buzz in ears, dizzines, deafness), methabolic acidosis Mechanis of action of acetylosalicylic acid (ASA) • irreversible inhibition od cyclooxygenases by acetylation of serine rest Ser HO O O O CH3 H C O COX OH + 3 + COX O O NH2 O NH2 HO O + OH O OH O O CH3 HO Metabolism of ASA O OH O O • HO O ASA proceeds in liver •all metabolits are excreted HO OH t1/2= 15 min. by urine O1-salicyoylglucuronic acid 5 % O OH OH glucuronation + CH3COOH O OH O HO O salicylic acid. 10 % conjugation with Gly O OH HO O O NH HO OH hydroxylation OH O1-(2-carboxyphenyl)glucuronic acid 10 % salicyluric acid (N-salicyoylglycine) O OH 75 % OH HO gentisic acid < 1 % Syntheses of ASA O OH O O OH Gerhardt, Justus Liebigs Ann. Chem. 87, 164 (1853) Gilm, Justus Liebigs Ann. Chem. 112, 181 (1859) OH H3C Cl O O Kraut, Justus Liebigs Ann. Chem. 150, 10 (1869) CH3 O H3C O OH O O OH H3C OH O O O Felix Hoffmann CH3 Other salicylates CH 3 CH3 CH3 O O O O O O F O O O O O O O Al Al Al OH O O O O O O F OH O O O O CH3 CH3 pentakis(acetylosalicyoyloxy)trialuminium dioxide 2',4'-difluoro-4-hydroxy-1,1'-biphenyl-3-carboxylic acid aloxiprin diflunisal Superpyrin® Unisal® tbl. Anthranilic acid derivatives – phenamates = substition derivatives of 2-phenylaminobenzooic acid •derived from salicylates by substitution of hydroxy group with (phenyl)amino moiety O OH 3 H R N R1 R2 •aromatic amino acids •substituted on the aniline ring only •inhibit both COX1 and COX2 (selectivity?; COX3?) •analgesics, antipyretics, antimigrenics, anti-inflammatory Phenamates O OH 3 H R N R1 R2 R1 R2 R3 Chemica name INN / preparation 2-(2,3-dimethylphenylamino)- -CH3 -CH3 -H mephenamic acid benzoic acid 2-(2,6-dichloro-3- -Cl -CH3 -Cl meclophenamic acid methylphenylamino)benzoic acid 2-(3-chloro-2- -CH3 -Cl -H tolphenamic acid methylphenylamino)benzoic acid Migea rapid® 2-(3-trifluoromethylphenylamino)benzoic -H -CF3 -H fluphenamic acid acid Tolphenamic acid Synthesis + N OH K O O O NH2 H CH 3 Br N + O 1.(CH COO) Cu, DMF Cl 3 2 2. H+ H3C Cl Kaltenbronn J.S. et al., Arzneim. Forsch 33, 621-627 (1983) Selectivity against COXs IC (COX1) 50 = 10 IC50 (COX 2) Grossmann C. J. et al., Inflammation Res. 44, 253-257 (1995) Niflumic acid and its esters F F F F F F H H C N N N O O OH OH 2-{[3-(trifluoromethyl)phenyl]amino}nicotinic acid fluphenamic acid niflumic acid •isosteric substitution benzene ⇒ pyridine, or –CH= ⇒ -N= •inhibit both COX1 and COX2 •anti-inflamatory, antirheumatics; usually topically administered Niflumic acid and its esters •esters are prodrugs which can better penetrate through the skin R 2-{[(3-trifluormethyl)phenyl]amino}nicotinic acid H niflumic acid Niflugel®, Nifluril® F F F H -||- 2-(morpholine-4-yl)ethylester N N N O morniflumate O O R -||- 1-oxo-2-(3H)-benzofurane-3-ylester talniflumate O O Aryl- and heteroarylalkanoic acids Structure-activity relationships (SAR) •the aliphatic part of the molecule is more specific for the effect than the aromatic one ARY O O ARY O ARY O O = = > > ARY OH ARY OH OH H3C OH OH ARY = aryl, heteroaryl Aryl- and heteroarylacetic acids and their functional derivatives O H2C Y R R = aryl or heteroaryl Y = OH, NHOH, NHR, OCH2COOH, or other • antirheumatics, anti-inflamatory, analgesics, antipyretics •inhibition of both COX1 and COX2 •adverse effects (AE) like in salicylates Aryl- and heteroarylacetic acids and their functional derivatives O (fenacs) H C O R Cl 3 Cl N NH CH3 O O O R O Cl R = H R = H [1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetic acid {2-[(2,6-dichlorophenyl)amino]phenyl}acetic acid indomethacin diclofenac •used since 1963 •used since 1975 •now mainly topically Voltaren®, Veral®, Myogit®, Dicloreum® Indobene® cps, Bonidon® gel, Elmetacin® spr R= OCH COOH R = OCH COOH 2 2 {2-[(2,6-dichlorophenyl)amino]phenyl}acetic acid [1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetic acid carboxymethylester caboxymethylester acemetacin aceclofenac Heteroarylacetic acids and their derivatives O O HN O N O O N O N O CH3 H3C N O H3C CH3 proglumetacin Cl Cl Cl N N N S OH OH O O [3-(4-chlorophenyl)-1-phenyl-1H-pyrazole-4-yl]acetic acid [4-(4-chlorophenyl)-2-phenyl-1,3-thiazole-5-yl]acetic acid lonazolac fentiazac •isosteres Aryl- a heteroarylacetic acids CH CH3 O O 3 O N N OH H2C OH OH O O O H C Cl Cl 3 H3C alclofenac tolmetin zomepirac Aryl- a heteroarylacetic acids •examples of isosterism of rings and functional groups O O OH OH O F N O Cl O S [1-(4-chlorobenzoyl)-5-methoxy-2-methyl- [6-fluoro-3-(4-methanesulfinylbenzylidene)-2-methyl- 1H-indol-3-ylacetic acid 3H-indene-1-yl]acetic acid indomethacin sulindac Nitrogeneous functional derivatives of aryl- and heteroarylacetic acids H3C O OH N O H 2-(4-butoxyphenyl)-N-hydroxyacetamide 2-(4-butoxyphenyl)acetohydroxamic acid bufexamac O Cl N H O N N CH O3 1,1´-biphenyl-4-yl-N-pyridine-2-yl-acetamide H C OH 3 O N difenpiramide H 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-yl]- N-hydroxyacetamide 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-yl]- acetohydroxamic acid oxametacin Nabumeton •a prodrug O OH O metabolism liver O O 4-(6-methoxynaphtalene-2-yl)butan-2-one 2-(6-methoxynaphtalene-2-yl)acetic acid (6MNA) nabumetone active metabolit Relifex® tbl.
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0156582 A1 Tsukamoto Et Al
    US 20090156582A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0156582 A1 Tsukamoto et al. (43) Pub. Date: Jun. 18, 2009 (54) PYRAZOLE COMPOUND Publication Classification (76) Inventors: Tetsuya Tsukamoto, Osaka-shi, (51) Int. Cl. Osaka (JP); Takeshi Yamamoto, A6II 3/55 (2006.01) Osaka-shi,Osaka (JP); Ryosuke A63L/454 (2006.01) Tokunoh, Osaka-shi, Osaka (JP); A63L/462 (2006.01) Tomohiro Kawamoto, Osaka-shi, C07D 403/02 (2006.01) Osaka (JP); Masahiro Okura, Osaka-shi, Osaka (JP); Masakumi (52) U.S. Cl. .................... 514/217.09: 514/406; 514/326; Kori, Osaka-shi, Osaka (JP); 548/364.1: 548/368.4: 546/211; 540/603 Katsuhito Murase, Osaka-shi, Osaka (JP) (57) ABSTRACT Correspondence Address: The present invention provides a pyrazole compound repre WENDEROTH, LIND & PONACK, L.L.P. sented by the formula (I): 1030 15th Street, N.W., Suite 400 East Washington, DC 20005-1503 (US) b (Io) (21) Appl. No.: 11/884,054 Ra R (22) PCT Filed: Feb. 9, 2006 (86). PCT No.: PCT/UP2006/302686 S371 (c)(1), wherein ring Ao is a pyrazole ring optionally further having 1 (2), (4) Date: Sep. 14, 2007 or 2 substituents; R is a substituted carbamoyl group; and R' (30) Foreign Application Priority Data is an optionally Substituted acylamino group, or a salt thereof or a prodrug thereof, which is useful as an agent for the Feb. 9, 2005 (JP) .................................. O333562005 prophylaxis or treatment of GSK-3? related pathology or Dec. 22, 2005 (JP) .................................. 3709622005 disease, and a GSK-3? inhibitor including same. US 2009/0156582 A1 Jun.
    [Show full text]
  • Sleason, Redwood City, CA (US), Juan W. W333. a 3. C
    USOO8288373B2 (12) United States Patent (10) Patent No.: US 8,288,373 B2 Chen et al. (45) Date of Patent: Oct. 16, 2012 (54) MODULATORS OF CXCR7 FOREIGN PATENT DOCUMENTS AU 2006-230674 A1 11, 2006 (75) Inventors: Xi Chen, Palo Alto, CA (US); Pingchen WO WOO2,08221 A2 1, 2002 Fan, Fremont, CA (US); Mark M. WO WOO3,O764OO A1 9, 2003 Sleason, Redwood City, CA (US), Juan W. W333. A 3. C. Jaen, Burlingame, CA (US). Lianfa WO WO 2007/126935 A2 11/2007 Li, Palo Alto, CA (US); Jeffrey P. WO WO 2008/008518 A1 1/2008 McMahon, Mountain View, CA (US); WO 2008, 11215.6 A1 9, 2008 Jay Powers, Pacifica, CA (US); Yibin Zeng, Foster City, CA (US); Penglie OTHER PUBLICATIONS Zhang, Foster City, CA (US) Konishi et al. (Yakugaku Zasshi (1973), 93(5), 684-7). Abstract.* r Miao et al., “CXCR7 (RDC1) promotes breast and lung tumor growth (73) Assignee: Chemocentryx, Inc., Mountain View, in vivo and is expressed on tumor-associated vasculature.” 2007. CA (US) PNAS, vol. 104. No. 40, pp. 15735-15740. c Zabel et al., “Elucidation of CXCR-7-Mediated Signaling Events and (*) Notice: Subject to any disclaimer the term of this Inhibition of CXCR4-Mediated Tumor Cell Transendothelial Migra patent is extended or adjusted under 35 tion by CXCR7 Ligands.” The Journal of Immunology, 2009, vol. U.S.C. 154(b) by 171 days. 183, Issue 5, pp. 3204-3211. International Search Reportmailed on Jan. 27, 2010, for International (21) Appl. No.: 12/612,638 Application No. PCT/US09/63298 filed on Nov.
    [Show full text]
  • Etats Rapides
    List of European Pharmacopoeia Reference Standards Effective from 2015/12/24 Order Reference Standard Batch n° Quantity Sale Information Monograph Leaflet Storage Price Code per vial Unit Y0001756 Exemestane for system suitability 1 10 mg 1 2766 Yes +5°C ± 3°C 79 ! Y0001561 Abacavir sulfate 1 20 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001552 Abacavir for peak identification 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001551 Abacavir for system suitability 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0000055 Acamprosate calcium - reference spectrum 1 n/a 1 1585 79 ! Y0000116 Acamprosate impurity A 1 50 mg 1 3-aminopropane-1-sulphonic acid 1585 Yes +5°C ± 3°C 79 ! Y0000500 Acarbose 3 100 mg 1 See leaflet ; Batch 2 is valid until 31 August 2015 2089 Yes +5°C ± 3°C 79 ! Y0000354 Acarbose for identification 1 10 mg 1 2089 Yes +5°C ± 3°C 79 ! Y0000427 Acarbose for peak identification 3 20 mg 1 Batch 2 is valid until 31 January 2015 2089 Yes +5°C ± 3°C 79 ! A0040000 Acebutolol hydrochloride 1 50 mg 1 0871 Yes +5°C ± 3°C 79 ! Y0000359 Acebutolol impurity B 2 10 mg 1 -[3-acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino] propoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! acetamide (diacetolol) Y0000127 Acebutolol impurity C 1 20 mg 1 N-(3-acetyl-4-hydroxyphenyl)butanamide 0871 Yes +5°C ± 3°C 79 ! Y0000128 Acebutolol impurity I 2 0.004 mg 1 N-[3-acetyl-4-[(2RS)-3-(ethylamino)-2-hydroxypropoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! butanamide Y0000056 Aceclofenac - reference spectrum 1 n/a 1 1281 79 ! Y0000085 Aceclofenac impurity F 2 15 mg 1 benzyl[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate
    [Show full text]
  • Antagonists of Il-6 to Prevent Or Treat
    (19) TZZ ¥_ _T (11) EP 2 376 126 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 39/00 (2006.01) C07K 16/24 (2006.01) 20.12.2017 Bulletin 2017/51 (86) International application number: (21) Application number: 09830695.4 PCT/US2009/006266 (22) Date of filing: 24.11.2009 (87) International publication number: WO 2010/065077 (10.06.2010 Gazette 2010/23) (54) ANTAGONISTS OF IL-6 TO PREVENT OR TREAT THROMBOSIS ANTAGONISTEN VON IL-6 ZUR PRÄVENTION ODER BEHANDLUNG VON THROMBOSE ANTAGONISTES D IL-6 POUR PRÉVENIR OU TRAITER LA THROMBOSE (84) Designated Contracting States: • MATSUYAMA MASASHI ET AL: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR "Anti-interleukin-6 receptor antibody HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL (tocilizumab) treatment of multicentric PT RO SE SI SK SM TR Castleman’s disease", INTERNAL MEDICINE, JAPANESE SOCIETY OF INTERNAL MEDICINE, (30) Priority: 05.02.2009 US 366567 TOKYO, JP; BIOSCIENCES INFORMATION 14.07.2009 US 502581 SERVICE, PHILADELPHIA, PA, US, vol. 46, 1 25.11.2008 US 117811 P January 2007 (2007-01-01), pages 771-774, 25.11.2008 US 117861 P XP002696891, ISSN: 0918-2918, DOI: 24.02.2009 US 391717 10.2169/INTERNALMEDICINE.46.6262 06.03.2009 US 399156 • EMILLE D ET AL: "ADMINISTRATION OF AN 25.11.2008 US 117839 P ANTI-INTERLEUKIN-6 MONOCLONAL 24.02.2009 US 391615 ANTIBODY TO PATIENTS WITH ACQUIRED IMUNODEFICIENCY SYNDROME AND (43) Date of publication of application: LYMPHOMA: EFFECT ON LYMPHOMA GROWTH 19.10.2011 Bulletin 2011/42 AND ON B CLINICAL SYMPTOMS", BLOOD, AMERICAN SOCIETY OFHEMATOLOGY, US, vol.
    [Show full text]
  • Objective Salicylate Propionic Acid Derivatives Acetic Acid
    Semester-IV Sub Name-medicinal chemistry-I (sub code-BP-402T) Objective Sodium salicylate, Aspirin, Mefenamic acid*, Meclofenamate, Indomethacin, Sulindac, Tolmetin, Zomepriac, Diclofenac, Ketorolac, Ibuprofen*, Naproxen, Piroxicam, Phenacetin, Acetaminophen, Antipyrine, Phenylbutazone. 1. INTRODUCTION A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti- inflammatory agents block certain substances in the body that cause inflammation. They are used to treat many different conditions. Some anti-inflammatory agents are being studied in the prevention and treatment of cancer. 1.1 CLASSIFICATION NSAIDs can be classified based on their chemical structure or mechanism of action. Older NSAIDs were known long before their mechanism of action was elucidated and were for this reason classified by chemical structure or origin. Newer substances are more often classified by mechanism of action. Salicylate • Aspirin (acetylsalicylic acid) • Diflunisal (Dolobid) • Salicylic acid and its salts Propionic acid derivatives • Ibuprofen • Dexibuprofen • Naproxen • Fenoprofen • Ketoprofen • Dexketoprofen Acetic acid derivatives • Indomethacin • Tolmetin • Sulindac • Ketorolac • Diclofenac • Aceclofenac • Nabumetone (drug itself is non-acidic but the active, principal metabolite has a carboxylic acid group) Enolic acid (oxicam) derivatives • Piroxicam • Meloxicam • Tenoxicam • Droxicam • Lornoxicam • Isoxicam (withdrawn from market 1985) • Phenylbutazone Anthranilic acid derivatives (fenamates) The following NSAIDs are
    [Show full text]
  • Novel Synthesis, Characterization and Biological Evaluation of Substituted Pyrazolidine-3, 5-Dione
    Central JSM Chemistry Research Article *Corresponding author Neeraj Upmanyu, School of Pharmacy & Research, By-Pass Road, Bhanpur, Bhopal (M.P.) -462027, Tel: 91- Novel Synthesis, 9425-128642; Email id: Submitted: 06 July 2015 Characterization and Biological Accepted: 31 August 2015 Published: 02 Spetmeber 2015 ISSN: 2333-6633 Evaluation of Substituted Copyright © 2015 Upmanyu et al. Pyrazolidine-3, 5-Dione OPEN ACCESS 1 1,2 1 Rohit Singh , Neeraj Upmanyu *, Manish Gupta and Pallavi Keywords Prasad3 • Pyrazolidine-3, 5-dione 1Department of Pharmaceutical Chemistry, R.K.D.F. College of Pharmacy, India • Benzoic acid 2School of Pharmacy and Research, Peoples University, India • Antibacterial & Anti-inflammatory 3School of Pharmaceutical Sciences, India Abstract An efficient lead molecule Pyrazolidine-3, 5-dione derivative has been developed as anti-inflammatory and antibacterial agents. In the present investigation, the compounds (RS-1 to RS-10) were synthesized according to Scheme 1 using 4-substituted benzoic acid as starting material. This acid is converted into the respective ester (R1 to R5) and then ester is converted into hydrazide (R2A1 to R2A5 & R2B1 to R2B5), and finally into the pyrazolidine-3,5-diones (tested compound). The compounds were evaluated for their anti-inflammatory activity by the carrageen an-induced paw edema method and anti-bacterial activity using zone of inhibition method. Out of these compounds RS-6, RS-9, RS-10, and RS-2 were found to be the most active synthesized compounds, with significant anti-inflammatory activity. The Structure Activity Relationship (SAR) of these synthesized compounds showed that substitution with Nitro and Chloro group at para position of phenyl ring is produce optimum activity, as among all the synthesized compounds, the most active ones were RS-6, RS-9, and RS-10.
    [Show full text]
  • Nucleosides, Nucleotides, Heterocyclic Compounds, Pyridine 2013
    Nucleosides, Nucleotides, Heterocyclic Compounds, Pyridine, Pyrimidine, Azaindole, Quinoline, Thiazole, Isatin, Phenanthrene, Thiophene We declare that some of the listed products might be protected by valid patents. They are only for scientific research and development purpose. They are not offered for sales in countries where the sales of such products constitutes patents infringement. The liability for patents checking and patents infringement is exclusive at buyers risk! I2CNS LLC CANNOT BE HELD LIABLE FOR ANY VIOLATIONS OF PATENT RIGHTS CAUSED BY CUSTOMERS. CAS No. Product Name and Description 26988-72-7 1-METHYL-DL-TRYPTOPHAN 68886-07-7 2-Fluoro-4-hydroxyphenylaceticacid 72607-53-5 N-(3-AMINOPROPYL)METHACRYLAMIDE 171049-41-5 7-AMINO-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLICACIDTERT- BUTYLESTER 885280-38-6 (3-OXO-CYCLOHEXYL)-CARBAMICACIDTERT-BUTYLESTER 186826-86-8 MOXIFLOXACIN HCL 102735-53-5 L-CYCLOPROPYLALANINE 145100-50-1 2-[N,N-BIS(TRIFLUOROMETHYLSULFONYL)AMINO]PYRIDINE 143491-57-0 Emtricitabine 39809-25-1 2-Amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-3,9-dihydropurin-6-one 147127-20-6 Tenofovir 716-39-2 2,3-NAPHTHALENEDICARBOXYLICANHYDRIDE 4333-62-4 1,3-DIMETHYLIMIDAZOLIUMIODIDE 108-45-2 m-Phenylenediamine 1961-72-4 R-(3)-HYDROXYMYRISTICACID 131-48-6 N-Acetylneuraminicacid 88196-70-7 (R)-1-(3-Methoxyphenyl)ethylamine 680-31-9 Hexamethylphosphoramide 486-66-8 Daidzein 872-50-4 1-Methyl-2-pyrrolidinone 425378-68-3 2-FLUORO-5-NITROPHENYLBORONICACIDPINACOLESTER 115651-29-1 5-ACETYL-2-AMINO-4-HYDROXYBENZOICACID 115269-99-3 N,N-BIS-BOC-N-ALLYLAMINE
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Documents Numérisés Par Onetouch
    19 ORGANISATION AFRICAINE DE LA PROPRIETE INTELLECTUELLE 51 8 Inter. CI. C07D 471/04 (2018.01) 11 A61K 31/519 (2018.01) N° 18435 A61P 29/00 (2018.01) A61P 31/12 (2018.01) A61P 35/00 (2018.01) FASCICULE DE BREVET D'INVENTION A61P 37/00 (2018.01) 21 Numéro de dépôt : 1201700355 73 Titulaire(s): PCT/US2016/020499 GILEAD SCIENCES, INC., 333 Lakeside Drive, 22 Date de dépôt : 02/03/2016 FOSTER CITY, CA 94404 (US) 30 Priorité(s): Inventeur(s): 72 US n° 62/128,397 du 04/03/2015 CHIN Gregory (US) US n° 62/250,403 du 03/11/2015 METOBO Samuel E. (US) ZABLOCKI Jeff (US) MACKMAN Richard L. (US) MISH Michael R. (US) AKTOUDIANAKIS Evangelos (US) PYUN Hyung-jung (US) 24 Délivré le : 27/09/2018 74 Mandataire: GAD CONSULTANTS SCP, B.P. 13448, YAOUNDE (CM). 45 Publié le : 15.11.2018 54 Titre: Toll like receptor modulator compounds. 57 Abrégé : The present disclosure relates generally to toll like receptor modulator compounds, such as diamino pyrido [3,2 D] pyrimidine compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR-8), and methods of making and using them. O.A.P.I. – B.P. 887, YAOUNDE (Cameroun) – Tel. (237) 222 20 57 00 – Site web: http:/www.oapi.int – Email: [email protected] 18435 TOLL LIKE RECEPTOR MODULATOR COMPOUNDS CROSS REFERENCE TO RELATED APPLICATIONS [0001] This application claims priority to U.S. Provisional Application Nos. 62/128397, filed March 4, 2015, and 62/250403, filed November 3, 2015, both of which are incorporated herein in their entireties for all purposes.
    [Show full text]
  • Patent Application Publication Oo) Pub. No.: US 2010/0129357 Al Garcia-Martinez Et Al
    US 20100129357A1 US 20100129357A1 (19) United States (12) Patent Application Publication oo) Pub. No.: US 2010/0129357 Al Garcia-Martinez et al. (43) Pub. Date: May 27,2010 (54) ANTIBODIES TO IL-6 AND USE THEREOF filed on Nov. 25, 2008, provisional application No. 61/117,811, filed on Nov. 25, 2008. (76) Inventors: Leon Garcia-Martinez, Woodinville, WA (US); Ann Elisabeth Carvalho Jensen, Publication Classification Edmonds, WA (US); Katie Olson, (51) Int. Cl. Kenmore, WA (US); Ben Dutzar, A61K 39/395 (2006.01) Seattle, WA (US); Ethan Ojala, A61P 37/02 (2006.01) Snohomish, WA (US); Brian Kovacevich, Snohomish, WA (US); (52) U.S. Cl.......................................................... 424/133.1 John Latham, Seattle, WA (US); Jeffrey T. L. Smith, Redmond, WA (US) (57) ABSTRACT Correspondence Address: The present invention is directed to therapeutic methods HUNTON & WILLIAMS LLP using IL-6 antagonists such as an Abl antibody or antibody INTELLECTUAL PROPERTY DEPARTMENT fragment having binding specificity for IL-6 to prevent or 1900 K STREET, N.W., SUITE 1200 treat disease or to improve survivability or quality of life of a WASHINGTON, DC 20006-1109 (US) patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of develop­ (21) Appl. No.: 12/502,581 ing) an elevated serum C-reactive protein level, reduced (22) Filed: Jul. 14, 2009 serum albumin level, elevated D-dimer or other cogulation cascade related protein(s), cachexia, fever, weakness and/or Related U.S. Application Data fatigue prior to treatment. The subject therapies also may (60) Provisional application No. 61/117,861, filed on Nov.
    [Show full text]
  • Mohammad Asif 1 Mohd Imran 2 and Asif Husain 3
    J. Chil. Chem. Soc., 66, N°2 (2021) APPROACHES FOR CHEMICAL SYNTHESIS AND DIVERSE PHARMACOLOGICAL SIGNIFICANCE OF PYRAZOLONE DERIVATIVES: A REVIEW MOHAMMAD ASIF 1 MOHD IMRAN 2 AND ASIF HUSAIN 3 1Department of Pharmacy, Himalayan Institute of Pharmacy and Research, Dehradun, (Uttarakhand), 248007, India. 2Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Northern Border University, Rafha 91911, PO Box 840, Saudi Arabia. 3Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Jamia Hamdard University, New Delhi, India. ABSTRACT Pyrazolone is a five-membered lactam ring containing two Nitrogens and one ketonic group in its structure. Numerous pyrazolone derivatives were exhibited with diverse biological, pharmacological, and chemical applications. When pyrazolones were discovered, they were only known as NSAIDs but in recent times they play a versatile role in several complications like cerebral ischemia, cardiovascular diseases, antibacterial, antioxidant, anticancer and several other pharmacological activities. Over the last few decades, pyrazolone derivatives have been used for various biochemical applications. Some of these derivatives such as metamizole, phenazone, aminopyrine, and propyphenazone, are widely used as anti-inflammatory and analgesics. The chemistry of pyrazolone has gained increasing attention due to its diverse pharmacological properties such as anticancer, analgesic, anti-inflammatory, antimicrobial, antioxidant, antifungal, antiviral, antidiabetic, and several other biological activities. Thus, keeping
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,173,622 B2 Wu Et Al
    US008173622B2 (12) United States Patent (10) Patent No.: US 8,173,622 B2 Wu et al. (45) Date of Patent: May 8, 2012 (54) ANTMICROBAL COMPOUNDS HAVING FOREIGN PATENT DOCUMENTS PROTECTIVE OR THERAPEUTICLEAVING JP O6049.220 A * 2, 1994 GROUPS JP O926.3731. A * 10, 1997 JP 2007-217683 A 8, 2007 (75) Inventors: Paul Hsien-Fu Wu, Edina, MN (US); WO WO 2007/O19478 A2 2, 2007 Catherine E. Taylor, Fridley, MN (US); OTHER PUBLICATIONS Linnus Cheruiyot, Andover, MN (US); English Machine translation of above JP 06049220A Feb. 1994 (9 Jianwei Li, Woodbury, MN (US); Terese pages). A. Bartlett, Forest Lake, MN (US); English Machine translation of above JP 09263.731A Oct. 1997 (43 Matt Bergan, Forest Lake, MN (US) pages). (PCT/US2009/053340) PCT Notification of Transmittal of the Inter national Search Report and the Written Opinion of the International (73) Assignee: Medtronic, Inc., Minneapolis, MN (US) Searching Authority. Database Registry, "Benzoic Acid, 4-(phenylmethoxy)-ethyl ester'. (*) Notice: Subject to any disclaimer, the term of this Nov. 16, 1984, XPOO2552306. patent is extended or adjusted under 35 Database Registry, Benzene, 1-methyl-1-(2-propen-1-yloxy) ethyl, U.S.C. 154(b) by 379 days. Nov. 16, 1984, XPOO25523.07. Database WPI Week 200780, Thomson Scientific, London, GB, AN (21) Appl. No.: 12/192,268 2007-864.588 & JP 2007 217683A (Hitachi Chem Co Ltd) Aug. 30, 2007, XP002662308. (22) Filed: Aug. 15, 2008 Yun-mi Kimetal. Structure-Antimicrobial Activity Relationship for Silanols, a New Class of Disinfectants, Compared with Alcohols and Prior Publication Data Phenols, International Journal of Antimicrobial Agents 29 (2007) (65) 217-222.
    [Show full text]